Kornimate/medical-research-clean huggingface dataset:
consequences of nocturnal and daytime hypoxemia in copd

Conditions: Chronic Obstructive Pulmonary Disease

Summary: we will determine whether oxygen therapy lowers the level of substances in the blood which cause inflammation, which is one of the adverse effects of copd and whether oxygen improves overall well being and quality of life as well as sleep quality.

hypothesis: isolated nocturnal hypoxemia contributes to chronic systemic inflammation in copd by activating circulating neutrophils.

Eligibility criteria:
inclusion criteria: * adult males or females with a diagnosis of copd screened for nocturnal desaturation as indicated above. * clinical stability defined by absence of treatment change or need for acute care within the last two months. * weight stable, within 5%, in the previous three months as measured during office visits. * willingness to participate in a clinical study. exclusion criteria: * acute illness within the preceding 2 months. * patients who received systemic glucocorticoid therapy within the past month. * clinical and/or overnight pulse oximetry evidence of obstructive sleep apnea (osa). the multivariate apnea prediction questionnaire (map) will be given to all patients to assess the likelihood of osa based on common symptoms of this disorder. while we recognize that this screening instrument was not evaluated specifically in copd patients, it assesses common signs and symptoms of osa. this tool has been shown to identify osa with 95% sensitivity (63). in addition, the odi 4% will be determined from the overnight pulse oximetry recording. patients will be excluded if the map score is \> 0.4 or if the odi 4% is \>15/hour, which is suggestive of the concomitant presence of obstructive sleep apnea. * hypercapnia defined as paco2 \> 50 mmhg on resting arterial blood gas * previous diagnosis of erythrocytosis, pulmonary vascular disease, pleural effusions, ischemic heart disease or congestive heart failure. * no chronic illnesses known to affect the inflammatory response such as infection, collagen vascular disease, liver disease, thyroid disease or diabetes. * primary care or pulmonary physician refusal. * patient refusal for any reason. * lack of capacity to participate in the informed consent process.
the test-to-prep study

Conditions: HIV Infections

Summary: to compare the effectiveness of two social network strategies (direct distribution and referral-based distribution) in increasing hiv self-testing (hivst) completion rates among social network contacts of current pre-exposure prophylaxis (prep) clients.


Eligibility criteria:
inclusion criteria - prep clients (egos): * stated willingness to provide informed consent. * stated willingness to comply with all study procedures. * stated availability for the duration of the study. * ability to identify members of their social network who may benefit from receiving an hivst kit and prep information. * currently prescribed prep by rapid clinics, including those initiating prep on the same day as study enrollment. inclusion criteria for peers (alters): - provision of electronic informed consent prior to completion of the quick response (qr)-linked survey instruments. exclusion criteria for prep clients (egos): * inability or refusal to provide informed consent (e.g., cognitive impairment). * unable or unwilling to comply with study procedures per study investigator * inability to identify members of their social network who may benefit from receiving an hivst kit and prep information. * aged 17 years or younger. exclusion criteria for peers (alters): * failure to provide electronic informed consent prior to starting qr-linked alter survey tools. * age 17 years or younger.
clinical trial of hydroquinone versus miconazol in melasma

Conditions: Melasma

Summary: melasma is an acquired discoloration of the skin characterized by brown colour changes commonly on the face.the duration of this double-blind clinical trial will be 12 weeks. the control group will receive treatment with topical hydroquinone (4%), and the other group topical miconazole. miconazol has antimelanotic properties and can be used as treatment for melasma patients. the estimated number of subjects to be recruited and randomized for the study is at least 30. the purpose of this study is determine if there is a difference in the effectiveness of these two agents. melasma area and severity index (masi) score will be assessed at the beginning of the study and at weeks 4, 8, and 12. photographs, colorimetry and histological assessment will be also evaluated. occurrence of adverse effects will also be recorded.

melasma is a common acquired hypermelanosis in dark skin populations, usually characterized by symmetrical, irregular macules occurring in photo-exposed areas such as face. treatment with depigmenting compounds such as hydroquinone, are still the gold standard in this condition. miconazol has depigmented properties that could be used as part of the treatment in melasma patients. this effect is exerted by inhibiting the tyrosinase enzyme. so, the primary objective of this study is to compare the depigmenting activity of miconazole against hydroquinone. patients who are included in the study will be randomly assigned to receive one of the treatments, which should use for 12 weeks. the medications should be applied in the affected regions twice a day. the evaluation of clinical improvement will be done in a blinded modality by means of the masi score, the global physician assessment, as well as colorimetry and histological melanin content. evaluations will be held on visits at 4, 8 and 12 weeks. skin biopsy will be taken at onset and at 12 weeks. at the end of the study, data will be compared concerning the former parameters. all side effects will be recorded and analysed.

Eligibility criteria:
inclusion criteria: * signed informed consent * mexican women over 18 years of age * dermatologic diagnostic of melasma * phototype iii or more exclusion criteria: * pregnant or breastfeeding * postbirth, abortion in the past 6 months * having an endocrine or autoimmune disease * under hormonal therapy of any kind including contraceptives or it´s use in the past 6 months * currently under treatment for melasma including sunblock * currently under radiation therapy, chemotherapy, immunosuppressants of any kind or phototherapy or it´s use in the past 6 months * having used or are consuming photosensitizing substances, oral or topical

Keywords: melasma, miconazole, hydroquinone
clinical trial of the effectiveness of the product cloratadd d (loratadine + pseudoephedrine sulfate) produced by the laboratory ems s/a, compared to the drug claritin d produced by schering-plough s/a, in patients with allergic rhinitis

Conditions: Allergic Rhinitis

Summary: the primary objective of this study is to evaluate the clinical efficacy of the drug cloratadd d ® (loratadine + pseudoephedrine sulfate - ems s/a) compared to the drug claritin d ® (loratadine + pseudoephedrine sulfate - schering plough) in patients with allergic rhinitis by quantification of the scores of clinical parameters (signs and symptoms) and laboratory (nasal flow) down through time.

secondly, it will be observed safety (tolerability) clinic after the administration of the drug in patients by comparing the clinical parameters and the incidence of adverse events.

Eligibility criteria:
inclusion criteria: 1. accept the consent form. 2. age between 18 and 60 years, regardless of sex; 3. agree to return to all evaluations of the study; 4. presenting the allergic symptoms confirmed by physical examination and by laboratory tests (ige and sensitivity to the mite dermatophagoides pteronyssinus), which should provide a diagnosis of allergic rhinitis with mild to moderate. exclusion criteria: 1. have participated in any experimental study or have ingested any drug trial in the 12 months preceding the start of the study; 2. made use of other medications that interfere with the regular response of the drug in the 4 weeks preceding the start of the study, such as steroids and antihistamines; 3. be patient with sensitivity loratadine / pseudoephedrine sulfate; 4. have any disease or anatomical abnormality in the upper airways is detrimental to the analysis of data, for example, tumors or septal deviations moderate and severe 5. demonstrate a history of alcohol abuse, drugs or pharmaceuticals. 6. have consumed alcohol within 48 hours prior to the period of hospitalization; 7. have a history of liver disease or kidney disease; 8. present framework of current asthma or recent (less than 1 year); 9. to present the severe pressure of any cause or be on medication for that; 10. smokers or patients who stopped smoking less than 06 months; 11. pregnant or nursing women; 12. patients with heart disease or who use medication for the cardiovascular system that is suffering interference of the drugs studied, for example, β-blockers; 13. patients using corticosteroids or other medicines that interact with the study drugs as monoamine oxidase; 14. patients with a history of glaucoma, urinary retention, and hyperthyroidism; 15. patients who have undergone facial plastic surgery that the physician's discretion, will interfere with nasal airflow

Keywords: reduction of signs and symptoms and enhanced nasal flow nasal flow
a united states extension study of corlux for recurrent psychotic symptoms in psychotic major depression

Conditions: Depressive Disorder, Major

Summary: corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress, triggering a healthy stress response. people who suffer from psychotic major depression may have unusually high levels of cortisol circulating within them or abnormal patterns of cortisol levels, overloading the stress response mechanism and causing symptoms of psychosis such as delusional thoughts or hallucinations. if corlux can keep the body's cortisol receptors from being overloaded, the stress response system may return to normal function, which may result in improvement of symptoms. the purpose of this study is to allow patients who have already participated in an earlier 8 week study of corlux versus placebo (an inactive pill) to receive additional courses of treatment with corlux periodically if a psychotic episode should reappear during a period of one year.


Eligibility criteria:
inclusion criteria: * completed participation through day 56 in corcept therapeutics protocol c-1073-07 * are 18 to 75 years of age * have a diagnosis of major depressive disorder with psychotic features (dsm-iv 296.24 or 296.34) * are able to provide written informed consent exclusion criteria: * have a major medical problem * have a history of an allergic reaction to corlux (c-1073, mifepristone)

Keywords: depression major depression psychotic major depression pmd psychosis
manual therapy in hemophilic arthropathy of the ankle

Conditions: Hemophilia A

Summary: introduction: haemophilic ankle arthropathy manifests as functional (deficit in muscle strength, mobility and proprioception), intra-articular degenerative alterations and chronic pain. manual therapy techniques are characterised by treating the soft tissues with the aim of modifying their density, relieving pain, reducing tissue sensitivity and improving the ranges of mobility. the objective is to evaluate the safety and effectiveness of a manual therapy protocol in patients with haemophilic ankle arthropathy. methods: randomised crossover clinical trial. 13 patients with haemophilic ankle arthropathy from different regions of spain will be recruited and randomised into two study groups (experimental and control). each session of the experimental group will last 50 minutes, with 1 physiotherapy session per week for a period of 3 weeks. patients will be evaluated at the beginning of the study, after the intervention and after a follow-up period of 4 weeks. the treatment programme includes 10 techniques that must be administered bilaterally. the study variables are the frequency of ankle haemarthrosis, range of movement, pressure pain threshold, pain intensity, joint status, biomechanical analysis of gait and balance, functionality and kinesiophobia. expected results: to evaluate the safety of manual therapy in patients with haemophilia. to observe changes in pain, mobility, joint condition, stability and functionality of the ankle, and kinesiophobia.


Eligibility criteria:
inclusion criteria: * patients diagnosed with haemophilia a and b * with severe haemophilia phenotype (\<1% fviii/fix) * over 18 years of age * with a medical diagnosis of ankle arthropathy and with clinical assessment using the hemophilia joint health score * on prophylactic or on-demand treatment with coagulation factor viii/fix concentrates exclusion criteria: * patients with neurological or cognitive disorders that prevent them from understanding the questionnaires and physical tests * failure to sign the informed consent document

Keywords: hemophilic arthropathy ankle manual therapy joint pain
cadonilimab in the treatment of recurrent/metastatic nasopharyngeal carcinoma

Conditions: Nasopharyngeal Carcinoma; Immune Checkpoint Inhibitors

Summary: this study is a single-arm, multicenter clinical study to evaluate the efficacy and safety of cadonilimab in combination with gemcitabine/cisplatin as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.


Eligibility criteria:
inclusion criteria: 1. the subject must sign the written informed consent form (icf) voluntarily； 2. age ≥18 years and ≤65 years； 3. subjects with histopathological diagnosis of nasopharyngeal carcinoma； 4. primarily metastatic (stage ivb as defined by ajcc staging system for npc, eighth edition) or recurrent/metastatic npc that is not amenable to local regional treatment or curative treatment and at least 6 months after radical treatment； 5. has not received prior systemic treatment; 6. has a performance status of 0 or 1 on the eastern cooperative oncology group (ecog) performance status 7. subject must have a measurable target lesion based on recist v1.1; exclusion criteria: 1. allergic to monoclonal antibodies, any cadonilimab components, gemcitabine, cisplatin, and other platinum drugs; 2. prior therapy as follow: anti-pd-1, anti-pd-l1 or anti-ctla-4; concurrent medical condition requiring the use of cortisol (\>10mg/day prednisone or equivalent dose) or other systematic immunosuppressive medications within 14 days before the study treatment（except：inhalation or topical corticosteroids）. 3. any active malignancy ≤ 2 years before randomization except for specific cancer under investigation in this study and any locally recurring cancer that has been treated curatively (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast)； 4. female patients who are at pregnancy or lactation.
extension trial of ublituximab and tgr-1202 in combination or as single agents in subjects currently receiving treatment on ublituximab and/or tgr-1202 trials

Conditions: Chronic Lymphocytic Leukemia; Non Hodgkin Lymphoma

Summary: this is an open label compassionate use trial of ublituximab and tgr-1202 in combination or as single agents in patients currently receiving treatment on ublituximab and/or tgr-1202 trials with b-cell non-hodgkin's lymphoma or chronic lymphocytic leukemia.


Eligibility criteria:
inclusion criteria: * subjects must be currently receiving treatment with ublituximab and/or tgr-1202 on a previously approved protocol. * subjects must have completed at least 6 cycles of therapy on their current protocol. exclusion criteria: * subject progressed while receiving therapy with ublituximab and/or tgr-1202 while participating in their immediate previous trial.
postprandial lipid metabolism in familial hypercholesterolaemia:effects of fish oils

Conditions: Hypertriglyceridaemia; Familial Hypercholesterolaemia

Summary: the purpose of this study is to determine whether fish oil supplementation is effective in the treatment of abnormal fat metabolism in subjects with elevated cholesterolaemia.

the use of statin therapy in familial hypercholesterolaemia (fh) is known to reduce cardiovascular risk and is a first line recommendation, however, there is considerable residual risk predicted by the presence of fasting and post-prandial hypertriglyceridaemia. this study will examine the effect of oral n-3 fatty acid ethyl esters supplementation (4g/day, omacor) on postprandial hypertriglyceridaemia and post-prandial arterial function when administrated to fh patients at increased risk of cardiovascular disease due to their residual fasting hypertriglyceridaemia.

Eligibility criteria:
inclusion criteria: * patients with fh (genetically defined ldl-receptor mutation or dutch score \>8) on statin treatment only * hypertriglyceridaemia on a random blood sample (triglycerides \>1.5mml/l) exclusion criteria: * subjects with diabetes mellitus * major systemic illness or use of steroids or other lipid-regulating drugs (such as niacin, fibrate and colesevelam) * patients on hypocaloric diets or ldl apheresis; anaemia, haemorrhage and pregnancy.

Keywords: familial hypercholesterolaemia postprandial dyslipidaemia fish oil treatment cardiovascular disease
explore the relationship between platelet count and bleeding score in itp

Conditions: ITP - Immune Thrombocytopenia

Summary: assessment of bleeding scores in immune thrombocytopenia purpuria to explore the relationship between platelet count and bleeding score in immune thrombocytopenia purpura (itp) and compare the clinical practicability of bleeding grading systems with adult patients with itp.

immune thrombocytopenia purpura (itp) is an autoimmune hemorrhagic disease, characterized by a decreased platelet count ( \< 100\*109) and suppressed platelet development . the incidence of itp increases with age, with an incidence rate of 20-40/ million adults (over 18 years old) /year and higher in the people over 60 years old . the main clinical manifestations were bleeding symptoms, but heterogeneity between manifestations was noted. severe thrombocytopenia is considered as a risk factor for bleeding in itp, but patients with moderate or even mild thrombocytopenia can also experience severe bleeding, which seems like a disproportionate performance . bleeding is one of the leading causes of death in patients with thrombocytopenia . bleeding manifestations in itp with mild mucocutaneous to life-threatening bleeding, and prediction of severe bleeding is instructive to the management of thrombocytopenia. bleeding assessment tools, such as itp bleeding assessment tool (itp-bat), itp bleeding scale (ibls) and khellaf bleeding score, have been developed and studied in a variety of clinical settings for diagnosis and to evaluate the severity of bleeding. in this study, investigators retrospectively assessed the relationship between platelet count and bleeding score in patients with itp and compared the clinical aspects of existing itp bleeding score systems .

Eligibility criteria:
inclusion criteria: * clinical diagnosis of primary itp . exclusion criteria: * malignancy disease * virus infection: * hiv * hepatitis b virus * hepatitis c virus * pregnancy.

Keywords: bleeding scores
efficacy study of olmesartan medoxomil on coronary atherosclerosis and epicardial adipose tissue(eat)

Conditions: Coronary Atherosclerosis

Summary: the purpose of this study is to determine whether olmesartan medoxomil is effective in the treatment of coronary atherosclerosis progression and epicardial adipose tissue(eat) volume reduction in patients with coronary atherosclerosis detected by coronary ct angiography(ccta).

epicardial adipose tissue(eat) is directly deposited around the pericardium and coronary artery. by means of paracrine action, it can generate various kinds of cytokines, inflammatory factor and free fatty acids, that can affect the state of coronary endothelial function, inflammation and oxidative stress, which finally aggravate the progression of coronary atherosclerosis. in recent years, clinical studies have shown that eat is a newly discovered independent risk factor of coronary atherosclerosis.studies confirm that olmesartan medoxomil can improve endothelial function, resisting thrombosis, improve tissue reconstruction, resisting oxidative stress so as to achieve atherosclerosis resistant. latest researches show that olmesartan medoxomil can better inhibit rat epididymal adipose cell hypertrophy and inflammatory reaction. coronary ct angiography(ccta) has emerged as a noninvasive imaging method for analysis coronary atherosclerosis. the purpose of this study is to determine whether olmesartan medoxomil is effective in the treatment of coronary atherosclerosis progression and eat volume reduction in patients with coronary atherosclerosis detected by ccta.

Eligibility criteria:
inclusion criteria: * coronary artery stenosis between 30% and 70% determined by ccta in essential hypertension patients * resting diastolic blood pressure (dbp) between 90 and 110 mmhg * type a and b for coronary artery vascular lesions exclusion criteria: * secondary hypertension * coronary artery stenosis less than 30% or greater than 70% determined by ccta * contraindications to treatment with olmesartan medoxomil (allergy, glaucoma, digestive ulcer, is currently taking phosphodiesterase-5 inhibitor) * resting systolic blood pressure (sbp) \> 200 mmhg or resting diastolic blood pressure (dbp) \> 110 mmhg * severe calcification, distortion or type c for coronary artery vascular lesions * pregnancy * unwillingness or inability to provide informed consent

Keywords: olmesartan medoxomil epicardial adipose tissue multidetector computed tomography
anomia treatment predictors

Conditions: Anomia (Word-Finding Impairment); Aphasia

Summary: the goal of this clinical trial is to identify predictors of response to phonological-focused anomia treatment in people with aphasia. the main question it aims to answer is who responds to which type of anomia treatment. researchers will compare phonomotor treatment and phonological components analysis to see which treatment is more beneficial, and for whom. participants will engage in both treatments over several months.

participants will complete screening and characterization testing to determine eligibility for the study. each treatment will be administered twice a week, for 10-15 sessions. pre-treatment and post-treatment testing will also occur for each treatment. there will be a period of no treatment in between the first and second treatment blocks.

Eligibility criteria:
inclusion criteria: * chronic aphasia (6+ months) * anomia * sufficient auditory comprehension to follow task instructions * phonologic impairment exclusion criteria: * progressive neurological illness or disease, including dementia * chronic medical illness that interferes with adherence to testing schedule * severe, uncorrected vision or hearing impairment that interferes with task completion * moderate-severe apraxia of speech or dysarthria that interferes with task completion

Keywords: anomia treatment aphasia treatment